Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akoustis Technologies, Inc. stock logo
AKTS
Akoustis Technologies
$0.60
$0.58
$0.45
$3.57
$59.16M1.66789,185 shs414,600 shs
Amarin Co. plc stock logo
AMRN
Amarin
$0.91
-0.9%
$0.94
$0.65
$1.49
$373.71M1.961.92 million shs464,000 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akoustis Technologies, Inc. stock logo
AKTS
Akoustis Technologies
0.00%+9.85%+4.02%+2.92%-79.31%
Amarin Co. plc stock logo
AMRN
Amarin
0.00%+4.01%-13.33%-22.88%-34.53%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akoustis Technologies, Inc. stock logo
AKTS
Akoustis Technologies
0.8035 of 5 stars
3.20.00.00.01.80.01.3
Amarin Co. plc stock logo
AMRN
Amarin
0.6784 of 5 stars
1.94.00.00.02.30.00.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akoustis Technologies, Inc. stock logo
AKTS
Akoustis Technologies
2.33
Hold$1.92219.44% Upside
Amarin Co. plc stock logo
AMRN
Amarin
1.75
Reduce$1.0819.05% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akoustis Technologies, Inc. stock logo
AKTS
Akoustis Technologies
$27.12M2.18N/AN/A$1.20 per share0.50
Amarin Co. plc stock logo
AMRN
Amarin
$306.91M1.22N/AN/A$1.35 per share0.67

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akoustis Technologies, Inc. stock logo
AKTS
Akoustis Technologies
-$63.56M-$0.97N/AN/AN/A-232.77%-80.80%-45.66%5/13/2024 (Estimated)
Amarin Co. plc stock logo
AMRN
Amarin
-$59.11M-$0.12N/AN/AN/A-18.96%-9.48%-6.34%8/7/2024 (Estimated)

Latest AKTS and AMRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024Q1 2024
Amarin Co. plc stock logo
AMRN
Amarin
-$0.0350-$0.02+$0.0150-$0.02$51.34 million$56.52 million    
2/29/2024Q4 2023
Amarin Co. plc stock logo
AMRN
Amarin
-$0.05-$0.01+$0.04-$0.01$72.46 million$74.71 million
2/13/202412/31/2023
Akoustis Technologies, Inc. stock logo
AKTS
Akoustis Technologies
-$0.18-$0.19-$0.01-$0.17$6.99 million$7.02 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akoustis Technologies, Inc. stock logo
AKTS
Akoustis Technologies
N/AN/AN/AN/AN/A
Amarin Co. plc stock logo
AMRN
Amarin
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akoustis Technologies, Inc. stock logo
AKTS
Akoustis Technologies
0.80
1.82
1.44
Amarin Co. plc stock logo
AMRN
Amarin
N/A
3.07
1.93

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Akoustis Technologies, Inc. stock logo
AKTS
Akoustis Technologies
28.84%
Amarin Co. plc stock logo
AMRN
Amarin
22.25%

Insider Ownership

CompanyInsider Ownership
Akoustis Technologies, Inc. stock logo
AKTS
Akoustis Technologies
5.60%
Amarin Co. plc stock logo
AMRN
Amarin
1.96%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Akoustis Technologies, Inc. stock logo
AKTS
Akoustis Technologies
22298.60 million93.08 millionOptionable
Amarin Co. plc stock logo
AMRN
Amarin
275410.67 million402.62 millionOptionable

AKTS and AMRN Headlines

SourceHeadline
Q2 2025 EPS Estimates for Amarin Co. plc Lowered by Zacks Research (NASDAQ:AMRN)Q2 2025 EPS Estimates for Amarin Co. plc Lowered by Zacks Research (NASDAQ:AMRN)
americanbankingnews.com - May 4 at 4:04 AM
Amarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Call TranscriptAmarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Call Transcript
finance.yahoo.com - May 3 at 8:34 PM
Q2 2025 EPS Estimates for Amarin Co. plc (NASDAQ:AMRN) Reduced by Zacks ResearchQ2 2025 EPS Estimates for Amarin Co. plc (NASDAQ:AMRN) Reduced by Zacks Research
marketbeat.com - May 3 at 11:37 AM
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
zacks.com - May 3 at 10:46 AM
Amarin (NASDAQ:AMRN) Issues Quarterly  Earnings Results, Beats Estimates By $0.02 EPSAmarin (NASDAQ:AMRN) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS
marketbeat.com - May 2 at 1:59 PM
Amarin First Quarter 2024 Earnings: EPS Beats ExpectationsAmarin First Quarter 2024 Earnings: EPS Beats Expectations
finance.yahoo.com - May 2 at 10:06 AM
Amarin’s Sell Rating Affirmed Amid US Market Challenges and Uncertain European GrowthAmarin’s Sell Rating Affirmed Amid US Market Challenges and Uncertain European Growth
markets.businessinsider.com - May 1 at 7:15 PM
Amarin Corp PLC (AMRN) Q1 2024 Earnings: Navigating Challenges with Strategic FocusAmarin Corp PLC (AMRN) Q1 2024 Earnings: Navigating Challenges with Strategic Focus
finance.yahoo.com - May 1 at 2:14 PM
Amarin Plc (AMRN) Q1 2024 Earnings Call TranscriptAmarin Plc (AMRN) Q1 2024 Earnings Call Transcript
fool.com - May 1 at 2:14 PM
Amarins (AMRN) Q1 Earnings and Revenues Surpass EstimatesAmarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates
zacks.com - May 1 at 1:36 PM
AMRN Stock Earnings: Amarin Corp Beats EPS, Misses Revenue for Q1 2024AMRN Stock Earnings: Amarin Corp Beats EPS, Misses Revenue for Q1 2024
investorplace.com - May 1 at 1:02 PM
Amarin: Q1 Earnings SnapshotAmarin: Q1 Earnings Snapshot
timesunion.com - May 1 at 7:51 AM
Amarin Reports First Quarter 2024 Business Update and Financial ResultsAmarin Reports First Quarter 2024 Business Update and Financial Results
globenewswire.com - May 1 at 7:00 AM
Heres what Wall Street expects from Amarins earnings reportHere's what Wall Street expects from Amarin's earnings report
markets.businessinsider.com - April 30 at 9:50 PM
Amarin Q1 2024 Earnings PreviewAmarin Q1 2024 Earnings Preview
msn.com - April 30 at 2:08 PM
Amarin Co. plc (NASDAQ:AMRN) Short Interest UpdateAmarin Co. plc (NASDAQ:AMRN) Short Interest Update
marketbeat.com - April 28 at 1:11 PM
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular EventAmarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
finance.yahoo.com - April 24 at 4:47 PM
Amarin Applauds HealthyWomens Citizens Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular EventAmarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
globenewswire.com - April 24 at 2:00 PM
Amarin Announces Results of Annual General Meeting of ShareholdersAmarin Announces Results of Annual General Meeting of Shareholders
globenewswire.com - April 22 at 8:00 AM
Amarin Corporation: Small Signs Of Recovery May Not Be EnoughAmarin Corporation: Small Signs Of Recovery May Not Be Enough
seekingalpha.com - April 18 at 12:18 AM
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
globenewswire.com - April 15 at 8:00 AM
Amarin Corporation plc: New REDUCE-IT Analyses Show VASCEPA/VAZKEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsAmarin Corporation plc: New REDUCE-IT Analyses Show VASCEPA/VAZKEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
finanznachrichten.de - April 8 at 8:22 AM
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
globenewswire.com - April 8 at 8:00 AM
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsNew REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
globenewswire.com - April 6 at 3:30 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Akoustis Technologies logo

Akoustis Technologies

NASDAQ:AKTS
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., designs, develops, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States, Asia, Europe, and internationally. It operates through Foundry Fabrication Services and RF Filters segments. The Foundry Fabrication Services segment provides engineering review and backend packaging services. Its RF Filters segment sells amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense applications. The company was founded in 2013 and is headquartered in Huntersville, North Carolina.
Amarin logo

Amarin

NASDAQ:AMRN
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.